Phase 1 multicenter, dose-escalation clinical study of the safety and tolerability of intravenously administered SNS-032 injection, a novel cyclin-dependent kinase inhibitor, administered to patients with advanced B-lymphoid malignancies

Trial Profile

Phase 1 multicenter, dose-escalation clinical study of the safety and tolerability of intravenously administered SNS-032 injection, a novel cyclin-dependent kinase inhibitor, administered to patients with advanced B-lymphoid malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs SNS 032 (Primary)
  • Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Sunesis Pharmaceuticals
  • Most Recent Events

    • 13 Apr 2017 Last checked against ClinicalTrials.gov.
    • 06 Jun 2012 Actual patient number changed from 40 to 21 as reported by ClinicalTrials.gov.
    • 19 May 2010 Status changed from active, no longer recruiting to completed, as results have been reported.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top